Targeted cancer drug combined with low-dose chemotherapy shrinks tumors, slows ovarian cancer
...t Cedars-Sinai Medical Center. The targeted drug, bevacizumab (Avastin TM ), is one of a new class of "anti-angi...ose of chemotherapy daily (taken in pill form) and bevacizumab by intravenous infusion. The investigators found that nearly half of the patients had no progressi...Cedars-Sinai medical tipsheet for June 2005
...t Cedars-Sinai Medical Center. The targeted drug, bevacizumab (Avastin TM ), is one of a new class of "anti-angiogenesis" drugs that prevents the growth of blood vessels that feed cancer tumors. PATIENTS WITH METABOLIC SYNDROME AND MODERATE LEVELS OF CORONARY CALCIUM FOUND TO HAVE A GREATER CHANCE OF HAVING B...Albert Szent-Gyrgyi Prize for Progress in Cancer Research to Harvard's Harold F. Dvorak, M.D.
... would probably not have had the therapeutic agent bevacizumab which has had a tremendous impact on improving survival for patients with advanced colorectal cancer, breast cancer, non-cell lung cancer and renal cell carcinoma", stated Chairman of the Szent-Gyrgyi Prize Committee Dr. Daniel Von Hoff, Vice Preside...Low-dose chemotherapy plus antiangiogenesis drug has activity in advanced breast cancer
... low-dose chemotherapy and the anti-VEGF antibody, bevacizumab (Avastin; Genentech) delayed the breast cancer's progression by an average of 5 months, compared to two months with the low-dose chemotherapy alone, said Harold Burstein, MD, PhD, a medical oncologist at Dana-Farber. He will present the results in a...Northwestern researchers launch Avastin trial for pancreatic tumors
...ersity Feinberg School of Medicine to determine if bevacizumab (also referred to as Avastin, an anti-angiogenesis drug that is designed to inhibit the growth of blood vessels in tumors) in combination with abdominal radiation therapy and chemotherapy can reduce localized pancreatic tumors that have not metastasi...New data at ASCO show CAMPTOSAR is key to treating 1st line metastatic colorectal cancer
...rvival (OS) for patients treated with FOLFIRI plus bevacizumab when compared with those who received mIFL plus be...e." The study also evaluated the impact of adding bevacizumab to FOLFIRI and mIFL. A statistically significant improvement in OS for patients treated with FOLFIRI...Comparison of patients' access to new and better cancer drugs reveals inequalities between countries
...s for both men and women [2]). The USA's uptake of bevacizumab for colorectal cancer was ten times the uptake of the European average. In Europe, Austria, France, Germany, Spain and Switzerland had uptake that was higher than the European average; Denmark, Hungry, Norway, Poland and Sweden had low uptake; and It...Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
...valuating the safety of a triplet therapy in which bevacizumab (Avastin) was added to the combination of ALIMTA p...stigational targeted anti-cancer agents, including bevacizumab (Avastin), erlotinib (Tarceva), cetuximab (Erbitux) and vandetanib (Zactima). ALIMTA is an antifol...GSK's Pazopanib shows positive results in patients with advanced RCC and ovarian cancer
...ogenesis drugs, including sunitinib, sorafenib and bevacizumab have demonstrated clinical activity in patients with advanced or metastatic RCC.8 Although targeted therapies have advanced the treatment of advanced or metastatic RCC, complete and durable responses are not achieved in the majority of patients8 and...GSK's Pazopanib shows positive results in patients with advanced renal cell carcinoma
...ogenesis drugs, including sunitinib, sorafenib and bevacizumab have demonstrated clinical activity in patients with advanced or metastatic RCC.8 Although targeted therapies have advanced the treatment of advanced or metastatic RCC, complete and durable responses are not achieved in the majority of patients8 and...Phase II study shows combination improves survival of metastatic melanoma patients
...it was thought that blocking VEGF with a drug like bevacizumab could facilitate the antitumor effects of chemotherapy in patients with metastatic melanoma. Bevacizumab is a monoclonal antibody that binds VEGF and blocks its interaction with cellular receptors. This action prevents new blood vessels from formin...Chemotherapy with bevacizumab increases risk of blood clots in arteries
... Institute . The combination of chemotherapy and bevacizumab has been shown to increase survival in patients wi... or older.) The clinical benefit associated with bevacizumab therapy was maintained for all subgroups. Although death from [a blood clot in the artery] was uncom...